Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo-controlled crossover laboratory study.

Ismene L Petrakis^1,2, Tracy Nolen³, Nathan Vandergrift³, Shawn Hirsch³, John H Krystal^1,2, Michael De Vivo⁴, Jeff Sabados⁴, Emily Pisani^1,2, Jenelle Newcomb^1,2, Thomas R Kosten⁵

¹Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, Connecticut, USA.

²Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.

³Social, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, North Carolina, USA.

⁴BioXcel Therapeutics Inc., New Haven, Connecticut, USA.

⁵Baylor College of Medicine, Houston, Texas, USA.

PubMed DOI

Abstract

BACKGROUND AND OBJECTIVES: Noradrenergic dysregulation is important in the pathophysiology of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD); pharmacotherapies targeting adrenergic function have potential as treatment for comorbidity. Dexmedetomidine (sublingual film formulation-BXCL501; IGALMI) is a highly potent, selective ⍺2-adrenergic receptor agonist and may be superior t…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.